NYSEARCA:REVS Columbia Research Enhanced Value ETF (REVS) Price, Holdings, & News → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free REVS Stock Alerts $23.16 +0.03 (+0.13%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$23.05▼$23.2750-Day Range$22.17▼$23.9752-Week Range$19.29▼$23.98Volume27,092 shsAverage Volume14,536 shsMarket Capitalization$41.68 millionAssets Under Management$40.41 millionDividend Yield2.07%Net Expense Ratio0.19% Stock AnalysisStock AnalysisChartHoldingsOwnershipRatingsStock AnalysisChartHoldingsOwnershipRatings Get Columbia Research Enhanced Value ETF alerts: Email Address About Columbia Research Enhanced Value ETFThe Columbia Research Enhanced Value ETF (REVS) is an exchange-traded fund that mostly invests in large cap equity. The fund tracks an index of US stocks pulled from the Russell 1000 Value Index. REVS index uses multifactor selection and market cap weighting. REVS was launched on Sep 25, 2019 and is managed by Columbia.Read More REVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REVS ETF News HeadlinesFebruary 9, 2024 | msn.comColumbia Banking System declares $0.36 dividendFebruary 1, 2024 | msn.comColumbia Sportswear GAAP EPS of $1.55 misses by $0.41, revenue of $1.06B misses by $20MApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.January 23, 2024 | benzinga.comColumbia Banking System's Earnings OutlookNovember 3, 2023 | investing.comMotilal Oswal S&P BSE Enhanced Value ETF (MOTE)October 23, 2023 | finance.yahoo.comColumbia Research Enhanced Real Estate ETF (CRED)April 13, 2023 | msn.comCaterpillar (CAT) Declares $1.20 DividendMarch 11, 2023 | seekingalpha.comVTV: No Value Left In Value StocksApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 22, 2023 | morningstar.comColumbia Overseas Value ASee More Headlines Receive REVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Columbia Research Enhanced Value ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerColumbia Fund NameColumbia Research Enhanced Value ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:REVS Inception Date9/25/2019 Fund ManagerChristopher Lo, Jason Wang WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkBeta Advantage Research Enhanced U.S. Value Index CategorySize and Style FocusLarge Cap Development LevelDeveloped Markets RegionNorth America Number of Holdings305 Fund Statistics Assets Under Management$40.41 million Average Daily Volume$0.00 Discount/Premium0.03% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorColumbia Management Investment Advisers, LLC CustodianThe Bank of New York Mellon Corporation DistributorALPS Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest100 shs Miscellaneous Outstanding Shares1,800,000Beta0.79 Creation Unit50,000 Creation Fee$500.00 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Columbia Research Enhanced Value ETF ExpensesTypeREVSLarge Cap ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.19%0.57%0.54%0.50%0.51%Other Expenses0.00%0.29%0.54%0.64%0.58%Total Expense0.19%0.64%0.70%0.74%0.70%Fee Waiver0.00%-0.19%-0.55%-0.68%-0.57%Net Expense0.19%0.61%0.60%0.58%0.58% Columbia Research Enhanced Value ETF (REVS) Holdings & ExposureTop 10 REVS HoldingsJPMorgan Chase & Co.(NYSE:JPM)Holding Weight: 4.72%Exxon Mobil(NYSE:XOM)Holding Weight: 4.41%Johnson & Johnson(NYSE:JNJ)Holding Weight: 4.06%Procter & Gamble(NYSE:PG)Holding Weight: 3.56%Bank of America(NYSE:BAC)Holding Weight: 3.09%Cisco Systems(NASDAQ:CSCO)Holding Weight: 2.79%Wells Fargo & Company(NYSE:WFC)Holding Weight: 2.48%Financial Select Sector SPDR Fund(NYSEARCA:XLF)Holding Weight: 2.13%Oracle(NYSE:ORCL)Holding Weight: 1.51%Citigroup(NYSE:C)Holding Weight: 1.45%REVS Sector ExposureREVS Industry ExposureFull Holdings Details Similar ETFsETRACS 2x Leveraged IFED Invest with the Fed TR Index ETNNYSEARCA:FEDLPacer CFRA-Stovall Equal Weight Seasonal Rotation Index ETFNYSEARCA:SZNEInvesco S&P 500 ex-Rate Sensitive Low Volatility ETFNYSEARCA:XRLVAllianzIM U.S. Large Cap Buffer10 Oct ETFNYSEARCA:OCTTFidelity International Value Factor ETFNYSEARCA:FIVAInstitutional OwnershipWealth Enhancement Advisory Services LLCBought 21,141 shares on 4/16/2024Ownership: 1.175%View All Institutional Transactions REVS ETF - Frequently Asked Questions How have REVS shares performed in 2024? Columbia Research Enhanced Value ETF's stock was trading at $21.65 on January 1st, 2024. Since then, REVS shares have increased by 7.0% and is now trading at $23.1552. View the best growth stocks for 2024 here. What does REVS invest in? Columbia Research Enhanced Value ETF is a equity fund issued by Columbia. REVS focuses on large cap investments and follows the Beta Advantage Research Enhanced U.S. Value Index. The fund's investments total to approximately $40.41 million assets under management. What stocks does Columbia Research Enhanced Value ETF hold? REVS invests in 305 holdings. Some of the stocks in their portfolio include JPMorgan Chase & Co. (JPM), Exxon Mobil (XOM), Johnson & Johnson (JNJ), Procter & Gamble (PG), Bank of America (BAC), Cisco Systems (CSCO), Wells Fargo & Company (WFC), Financial Select Sector SPDR Fund (XLF), Oracle (ORCL) and Citigroup (C). What is the management fee for Columbia Research Enhanced Value ETF? Columbia Research Enhanced Value ETF's management fee is 0.19% and has no other recorded expenses or fee waivers. The net expense ratio for REVS is 0.19%. Who are Columbia Research Enhanced Value ETF's major shareholders? Columbia Research Enhanced Value ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wealth Enhancement Advisory Services LLC (1.17%). How do I buy shares of Columbia Research Enhanced Value ETF? Shares of REVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:REVS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Columbia Research Enhanced Value ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
